@doctorly and @dr.ljmaxfield say it best you deserve proof, not promises. That’s why we didn’t settle for the usual testing you see in skincare. We went further, running an IRB-approved, randomized, double-blind clinical trial. This level of rigor is the gold standard in science, almost always reserved for pharmaceuticals because of its high cost and the risk involved. There’s no guarantee your product will come out on top and if it underperforms, that data still gets published. But we believe so deeply in our formula, and we believe your skin deserves the same standards of proof. Over 12 weeks, Needle-less® Growth Factor Serum went head-to-head with SkinMedica’s $295 TNS Advanced+ Serum. The results? DRMTLGY outperformed in 73% of key performance measures, with more participants showing visible improvements in firmness, smoothness, and fine lines. *Based on a 12-week double-blind IRB-approved clinical trial of 20 participants.